Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058525 | 1.00 | TRPV1 (0.50) | TRPV1FAAHTSHRHIF1AMAPT | |
| SCHEMBL28245143 | 0.80 | TRPV1 (0.36) | TRPV1FAAHMAPTALDH1A1CYP3A4 | |
| SCHEMBL28151994 | 0.77 | MEN1 (0.50) | TRPV1FAAHTSHRMAPTALDH1A1 | |
| SCHEMBL73315 | 0.77 | MEN1 (0.50) | TRPV1FAAHTSHRMAPTALDH1A1 | |
| SCHEMBL73313 | 0.77 | MEN1 (0.50) | TRPV1FAAHTSHRMAPTALDH1A1 | |
| SCHEMBL4284074 | 0.75 | SPHK2 (0.37) | TRPV1MAPTALDH1A1CYP3A4LMNA | |
| SCHEMBL5613599 | 0.75 | MEN1 (0.53) | TRPV1FAAHMAPTALDH1A1CYP3A4 | |
| SCHEMBL5613640 | 0.75 | MEN1 (0.53) | TRPV1FAAHMAPTALDH1A1CYP3A4 | |
| SCHEMBL5613660 | 0.75 | MEN1 (0.53) | TRPV1FAAHMAPTALDH1A1CYP3A4 | |
| SCHEMBL2004490 | 0.75 | MEN1 (0.53) | TRPV1FAAHMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | claimed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | claimed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | claimed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | claimed |
| WO-2022132902-A1 | CAPSAICIN AND TRPV1 MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF | PANO THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2020252046-A1 | CAPSAICIN AND TRPV1 MODULATOR COMBINATIONS AND METHODS OF USE THEREOF | PANO THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-9901565-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9801850-B2 | Antibacterial agent | OSAKA UNIVERSITY (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | PROTECTEA, LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2460405-B1 | EPIGALLOCATECHIN GALLATE DERIVATIVE AS ANTIBACTERIAL AGENT | UNIV OSAKA (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-8952055-B2 | Membrane fusion inhibitor | PROTECTEA, LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2460405-A1 | ANTIBACTERIAL AGENT | Osaka University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120136049-A1 | ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | KAIHATSU, Kunihiro (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-1069105-B1 | CAPSAICINOIDE-LIKE SUBSTANCES HAVING ESTER BOND | AJINOMOTO KK (JP) | 2007-09-19 | — | — | EP | disclosed |
| US-6333421-B1 | SUBSTANCES HAVING IMMUNOPOTENTIATING AND ENERGY METABOLISM ENHANCING ACTIVITY | MORINAGA & CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1069105-A1 | NOVEL CAPSAICINOIDE-LIKE SUBSTANCES HAVING ESTER BOND | MORINAGA & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136049-A1 | ANTIBACTERIAL AGENT | TEAD4, ELOVL6, TEAD1 | TRPV1 734/4885FAAH 2034/4885TSHR 2877/4885 |
| US-20150111961-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | TRPV1 764/4885FAAH 519/4885TSHR 2134/4885 |
| US-20110003889-A1 | MEMBRANE FUSION INHIBITOR | FLOT1, NSF, VAMP7 | TRPV1 764/4885FAAH 519/4885TSHR 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.